Bailard Inc. Purchases Shares of 29,769 Protara Therapeutics, Inc. (NASDAQ:TARA)

Bailard Inc. acquired a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 29,769 shares of the company’s stock, valued at approximately $157,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TARA. XTX Topco Ltd bought a new stake in Protara Therapeutics during the 3rd quarter valued at $60,000. Geode Capital Management LLC grew its stake in shares of Protara Therapeutics by 21.0% in the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after purchasing an additional 29,514 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of Protara Therapeutics by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after purchasing an additional 51,944 shares during the period. 38.13% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $20.00 target price on shares of Protara Therapeutics in a research report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th.

Protara Therapeutics Stock Performance

TARA opened at $3.63 on Thursday. The stock’s fifty day moving average is $4.63 and its 200-day moving average is $3.39. Protara Therapeutics, Inc. has a one year low of $1.60 and a one year high of $10.48. The company has a market capitalization of $74.89 million, a PE ratio of -1.29 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.09. On average, equities research analysts forecast that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.